UIPL

On October 9, 2024, as part of regular meetings, a session was held between the UIPL Regulatory Working Group and the Agency for Medicines and Medical Devices of Bosnia and Herzegovina (ALMBIH), represented by the Agency’s Director, Nataša Grubiša, and Ana Petrović, Director of the Association of Innovative Pharmaceutical Manufacturers (UIPL). This meeting was part […]

With the aim to increase transparency and improve access to data, the EFPIA has voluntarily created the European Gateway map. This is a unique platform with information on member companies. In addition to the transparency in disclosure of relationships with patient organisations, the research-based pharmaceutical industry has committed to disclose details of payments and other […]

One of the most important amendments of the Code of Conduct pertains to the selection of appropriate and permitted locations for the organisation of conferences, symposiums, workshops, and all other forms of meetings. UIPL has prepared eligible criteria for meetings venue which relate the acceptability of hotels that meet or fail to meet conditions outlined […]

UIPL – Association of Innovative Pharmaceutical Manufacturers in Bosnia and Herzegovina as a member of the EFPIA, adopted the first Code of Conduct of Inovative Pharamaceutical Companies in 2016.  According to the changes in the industry, at the general Assembly held on March 30, 2023 UIPL once again, harmonized the Code with all the new […]

Can healthcare be an example of a profitable investment? How is health care viewed in BiH? What is digitalisation in healthcare and how is it introduced? How much does digitisation cost? These are just some of the questions that the First Forum: “Health System as an Investment” will try to provide answers to. Representatives of […]